News

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.
Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...
Williams-Sonoma’s first quarter results were met with a negative market reaction, as profit fell short of Wall Street’s ...
SNS Insider Reveals Sharp Growth in U.S. Retinal Biologics Market, Valued at USD 9.70 Billion in 2023 Capturing Over 43% Global Share Amid FDA Approvals, VEGF-A Dominance, and Accelerating R&D in ...